Empowering nurses and midwives: the evidence-base for the Nurses and Midwives Certification Programme of ESHRE†.

Study Question: How were the logbook and curriculum for the Nurses and Midwives Certification Programme of ESHRE developed?

Summary Answer: The logbook and corresponding curriculum for the ESHRE Nurses and Midwives Certification Programme were based on an extensive literature review, an international expert panel, and a survey of Belgian and Dutch nurses and midwives (N&M) working in reproductive medicine (RM).

What Is Known Already: ESHRE has been running a certification programme for N&M working in RM since 2015. To the best of our knowledge, clinical practice guidelines for nursing/midwifery care within RM are lacking as is consensus on role descriptors of N&M working in RM.

Qualitative risk assessment of follicle stimulating hormone injectable products.

Background: Gonadotropin injections for fertility treatment regimens are usually self-injected, typically over 8-12 days during the assisted reproductive technology cycle. Parenteral gonadotropins are available in different formulations and administered through various systems. A user experience study and risk assessment were performed to evaluate different product types for risks to the patient when preparing and administering injections.

Bemfola fixed dose pens potentially reduce drug wastage and associated costs of infertility treatment.

Bemfola is a recombinant follicle-stimulating hormone (FSH) used during infertility treatment. One main differentiator between FSH products is their delivery device; consisting of multi-dose pens (Gonal-f), vials or multi-dose preparations (Menopur), or adjustable daily disposable dose pens (Bemfola). To determine the potential impact of delivery device on drug wastage during infertility treatment this study retrospectively analysed Gonal-f and Menopur prescription and usage data from five UK clinics.